mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
Drs. Swami and Ciuro discuss real-world data that indicates a shift in mHSPC treated with intensified therapy since 2023.
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
A recent study evaluated the impact of early withdrawal of upfront ARSIs on clinical outcomes in patients with mCSPC.
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
Patients with mHSPC who are younger, have a high BMI, or have low-volume disease may benefit more from treatment with ARPIs.
In the final segment, the panel emphasizes the importance of trust in the patient-provider relationship.
The panel exchanges strategies on sequencing and debates the potential of immunotherapy in prostate cancer.
In part four, the panel shares thoughts on the implications of recent trials including ARASENS, ARANOTE, and PEACE-3.
The panel discusses nuances to consider when using PSMA PET imaging, including differentiating false positives.
Experts discuss managing prostate cancer progression, risk stratification, and balancing treatment with quality of life.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.